559 reports of this reaction
2.3% of all BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE reports
#8 most reported adverse reaction
DIZZINESS is the #8 most commonly reported adverse reaction for BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE, manufactured by Actavis Pharma, Inc.. There are 559 FDA adverse event reports linking BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE to DIZZINESS. This represents approximately 2.3% of all 24,476 adverse event reports for this drug.
Patients taking BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 559 FDA reports for BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 2.3% of all adverse event reports for BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE, making it a notable side effect.
If you experience dizziness while taking BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.